Bearish flow noted in Replimune Group with 1,531 puts trading, or 1.3x expected. Most active are Dec-23 5 puts and Dec-23 10 puts, with total volume in those strikes near 1,400 contracts. The Put/Call Ratio is 20.69, while ATM IV is up nearly 24 points on the day. Earnings are expected on February 8th.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REPL:
- Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
- Replimune Group presents updated data on RP2 in uveal melanoma
- Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
- Replimune Group reports Q2 EPS (90c), consensus (86c)
- Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)